Rasbelon (Rasburicase) 1.5mg Injection is a medication used to treat hyperuricemia (high levels of uric acid in the blood) in patients with cancer, especially those undergoing chemotherapy. It is a recombinant urate oxidase enzyme that converts uric acid into allantoin, a compound that is easily excreted by the kidneys.
Composition: Each vial of Rasbelon contains 1.5mg of Rasburicase (an active pharmaceutical ingredient).
Mechanism of Action: Rasbelon works by converting uric acid into allantoin, which is then excreted by the kidneys. This reduces the level of uric acid in the blood and prevents its accumulation in the kidneys, joints, and other tissues.
Dosage: The recommended dose of Rasbelon is 0.2mg/kg administered intravenously over 30 minutes once daily. The dosage may be adjusted based on individual patient response and serum uric acid levels.
Uses: Rasbelon is used to treat:
- Hyperuricemia (high levels of uric acid in the blood) in patients with cancer, especially those undergoing chemotherapy
- Prevention of tumor lysis syndrome (TLS) in patients with cancer
- Treatment of severe hyperuricemia (high levels of uric acid in the blood) in patients with gout
Side Effects: Common side effects of Rasbelon include:
- Hypersensitivity reactions, including anaphylaxis
- Flu-like symptoms, such as fever, chills, and headache
- Nausea and vomiting
- Abdominal pain
- Diarrhea
- Fatigue
Rare but serious side effects include:
- Hemolytic anemia (blood disorder)
- Thrombocytopenia (low platelet count)
- Neutropenia (low white blood cell count)
- Hypersensitivity reactions, including anaphylaxis
Recommendation: Rasbelon is recommended for patients with cancer who are undergoing chemotherapy and have hyperuricemia. Patients with a history of hypersensitivity reactions to Rasburicase or other enzymes should not receive Rasbelon.
Important Note:
- Rasbelon should be used under the guidance of a healthcare provider with experience in the treatment of cancer and hyperuricemia.
- Patients with a history of kidney disease or liver disease should be closely monitored while taking Rasbelon.
- Rasbelon may interact with other medications, such as chemotherapy agents, immunosuppressants, and diuretics. Patients should inform their healthcare provider of all medications they are taking before starting Rasbelon therapy.
- Patients should be advised to report any symptoms of hypersensitivity reactions, such as rash, itching, swelling, or difficulty breathing.
Reviews
There are no reviews yet.